Associated Papers
Case Report: Refractory systemic nmastocytosis with AML1::ETO+ acute myeloid leukemia driven by rare KIT mutation: remarkable therapeutic efficacy of avapritinib.
Xue S et al.
Frontiers in Pediatrics, 2025
[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].
Ueyama J et al.
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2012
Select a paper to view details